Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
MDU Resources Group Q1 2026 Earnings Call - Bakken East Pipeline Demand Surges
MDU Resources Group reported Q1 2026 earnings of $0.39 per share, a slight dip from the prior year, primarily due to mild winter weather that reduced earnings by approximately $0.03 per share. Despite...
- Q1 2026 earnings of $0.39 per share were slightly below prior year due to mild winter weather, which reduced earnings by approximately $0.03 per share.
- Bakken East Pipeline Project open season concluded with approximately 1.4 billion cubic feet per day of submitted interest, with 40% under signed precedent agreements.
- Projected capital investment for the Bakken East Pipeline ranges from $2.7 billion to $3.2 billion, incremental to the current $3.1 billion capital plan.
- +7 more takeaways
American States Water Q1 2026 Earnings Call - Rate Hikes and Infrastructure Spend Drive 8.6% EPS Growth
American States Water delivered a solid first quarter, with consolidated earnings per share rising 8.6% year-over-year to $0.76. The gain was fueled by step-rate increases in both its water and electr...
- Consolidated earnings per share rose 8.6% year-over-year to $0.76, outpacing the $0.70 reported in Q1 2025.
- Water utility earnings increased to $0.55 per share, driven by new 2026 water rates and advice letter capital projects, partially offset by higher water supply costs.
- Electric segment earnings grew to $0.08 per share, supported by fourth-year rate increases, though higher operating and interest expenses tempered gains.
- +16 more takeaways
Coeur d'Alene Mines Corporation Q1 2026 Earnings Call - Record Cash Flow and New Gold Integration Drive North American Precision Metals Platform
Coeur d'Alene Mines Corporation delivered a record first quarter in 2026, driven by its newly acquired New Gold assets and strong operational performance across its North American portfolio. Revenue s...
- Record Q1 2026 revenue of $856 million, up significantly year-over-year, driven by higher production and favorable metal prices.
- EBITDA surged nearly four-fold year-over-year to a record $475 million, reflecting the immediate impact of the New Gold acquisition.
- Free cash flow reached $267 million, the second-highest in company history, despite over $200 million in one-time and transaction-related costs.
- +11 more takeaways
Endeavour Silver Q1 2026 Earnings Call - Record Production and Revenue Surge with Pitarrilla Feasibility on Track
Endeavour Silver delivered a breakout first quarter in 2026, shattering prior-year records with nearly 2 million ounces of silver and 12,000 ounces of gold produced, alongside a 230% revenue jump to $...
- Record Q1 2026 production: Nearly 2 million ounces of silver and 12,000 ounces of gold, representing a 78% increase year-over-year, driven by the inclusion of Kolpa and Terronera.
- Revenue and cash flow surge: Revenue jumped 230% to $210 million, while mine operating cash flow before taxes rose 400% to $115 million, demonstrating strong operational leverage.
- Cost structure shifts: All-in sustaining costs rose 51% to $37/oz due to the inclusion of higher-cost assets and initial ramp-up inefficiencies, but management expects further reductions as operations normalize and ore grades improve in H2 2026.
- +7 more takeaways
CVS Health Q1 2026 Earnings Call - EPS Guidance Raised to $7.30-$7.50 on Strong Aetna & Pharmacy Execution
CVS Health delivered a robust first quarter in 2026, reporting adjusted EPS of $2.57 and driving enough momentum to raise full-year adjusted EPS guidance to $7.30-$7.50. The standout performer was the...
- Full-year adjusted EPS guidance raised to $7.30-$7.50, up from $7.00-$7.20, reflecting strong Q1 performance and disciplined execution across segments.
- Aetna segment adjusted operating income surged to approximately $3 billion, driven by a medical benefit ratio of 84.6% and favorable prior-year development.
- Management reaffirmed confidence in returning Medicare Advantage margins to target levels by 2028, despite 2027 rate notices remaining insufficient to offset medical cost trends.
- +7 more takeaways
The RMR Group Q2 2026 Earnings Call - Incentive Fees Surge as Fundraising Hits Geopolitical Headwinds
The RMR Group delivered a solid fiscal second quarter, with distributable earnings of $0.44 per share and adjusted EBITDA of $18.5 million, hitting the high end of guidance despite a turbulent macro b...
- Distributable earnings of $0.44 per share and adjusted EBITDA of $18.5 million met the high end of guidance, demonstrating operational resilience in a volatile market.
- Incentive fees are back on track for 2026, following $23.6 million earned in 2025, as managed REITs DHC and ILPT delivered exceptional total shareholder returns.
- DHC’s operational momentum is clear, with same-property NOI up 13.5% and occupancy rising 110 basis points, prompting a Moody’s upgrade to a positive outlook.
- +7 more takeaways
American Homes 4 Rent Q1 2026 Earnings Call - Record Leasing Volumes and Strategic Capital Recycling Drive NOI Growth
American Homes 4 Rent (AMH) delivered a resilient first quarter in 2026, with record leasing volumes and strong execution offsetting a late start to the seasonal peak. Core FFO grew 4.6% year-over-yea...
- Core FFO per share grew 4.6% year-over-year to $0.48, while Adjusted FFO rose 8% to $0.45, reflecting solid operational execution despite a late start to the leasing season.
- Record leasing volumes in March and April drove new lease spread improvements to 1.2% and same-home average occupied days to 95.6%, signaling strong momentum as peak season accelerates.
- Same-home Core NOI increased 3.7% year-over-year, fueled by a 200 basis point acceleration in new lease spreads and disciplined control of controllable operating expenses.
- +7 more takeaways
Palomar Holdings Q1 2026 Earnings Call - Profitable Growth Accelerates Amid Shifting Market Cycles
Palomar Holdings delivered a robust first quarter, marking its 14th consecutive earnings beat with adjusted net income surging 23% to $63.1 million. The company’s diversified specialty portfolio, span...
- Adjusted net income grew 23% to $63.1 million, extending a streak of 14 consecutive quarterly earnings beats.
- Gross written premiums surged 42% year-over-year to $629.8 million, driven by broad-based growth across all five product categories.
- Adjusted combined ratio stood at 76%, reflecting higher attritional losses from casualty and crop expansion, offset by disciplined expense management.
- +11 more takeaways
Royal Gold Inc. Q1 2026 Earnings Call - Record Revenue and Cash Flow Surge, Aggressive Capital Allocation Tools Added
Royal Gold delivered a transformative first quarter of 2026, posting record revenue of $469 million, record operating cash flow of $294 million, and adjusted net income of $233 million. The results we...
- Record financial performance: Q1 2026 revenue hit $469 million (up 143% YoY), operating cash flow reached $294 million (up 115% YoY), and adjusted net income was a record $233 million, or $2.72 per share (up 80% YoY).
- Metal price tailwinds: Significant price appreciation drove results, with gold up 70%, silver up 165%, and copper up 38% year-over-year. Gold contributed 71% of revenue, while silver rose to 16%.
- Successful Bear Creek restructuring: The company converted its Bear Creek debt and equity interests into cash, Highlander Silver shares (which were sold), and core royalty interests in the Corani project and Mercedes mine, aligning better with its core business model.
- +7 more takeaways
Genmab Q1 2026 Earnings Call - EPKINLY Momentum and Rina-S Catalysts Drive 25% Revenue Growth
Genmab delivered a robust Q1 2026, with total revenue surging 25% year-over-year to $176 million in proprietary sales. The growth was anchored by EPKINLY, which posted 52% global growth and expanded i...
- Total revenue grew 25% year-over-year in Q1 2026, driven by strong performance across the proprietary portfolio and sustained royalty streams from Darzalex and Kesimpta.
- EPKINLY sales jumped 52% globally to $137 million, benefiting from a fixed-duration label in second-line follicular lymphoma and expanded adoption in community settings.
- The FDA removed the 24-hour hospitalization requirement for EPKINLY in third-line plus DLBCL, a regulatory shift expected to accelerate outpatient use and broaden market penetration.
- +9 more takeaways